Description
Lenvazee 4 mg contains Lenvatinib, a multi-targeted tyrosine kinase inhibitor (TKI) designed to block key receptors responsible for cancer cell proliferation and blood vessel formation. It plays an important role in modern targeted oncology therapy.
🔬 Mechanism of Action
Lenvatinib inhibits several receptor tyrosine kinases including:
- VEGFR (Vascular Endothelial Growth Factor Receptors)
- FGFR (Fibroblast Growth Factor Receptors)
- PDGFR, RET, and KIT
As a result, it reduces tumor angiogenesis and slows cancer cell growth, helping delay disease progression.
💊 Indications
Lenvazee 4 mg is indicated for:
- Radioactive iodine-refractory differentiated thyroid cancer (DTC)
- Unresectable hepatocellular carcinoma (HCC)
- Advanced renal cell carcinoma (RCC) (in combination therapy)
- Advanced endometrial carcinoma (in combination therapy)
📌 Key Features of Lenvazee 4 mg
- Strength: 4 mg
- Dosage Form: Oral capsule
- Therapeutic Class: Multi-targeted Tyrosine Kinase Inhibitor
- Administration: Taken orally once daily; total daily dose may vary depending on indication
- Monitoring: Blood pressure, liver function, thyroid function, renal function, and proteinuria monitoring required
⚕️ Benefits of Lenvatinib
- Broad-spectrum targeted therapy
- Oral administration for patient convenience
- Effective in multiple advanced cancers
- Helps control tumor progression
⚠️ Precautions
- May cause hypertension, diarrhea, fatigue, and decreased appetite
- Risk of proteinuria and liver dysfunction
- Dose adjustments may be required based on tolerance
- Regular monitoring essential during therapy
- Use strictly under oncologist supervision
